Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 2
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
Effectiveness of biological therapy in reducing psoriasis-related cardiovascular risk.
Boskovic S, Borriello S, D'Ascenzo F, Sciamarrelli N, Rosset F, Mastorino L, Paolo D, Bocchino PP, De Filippo O, Ribero S, De Ferrari G, Quaglino P. Boskovic S, et al. Among authors: borriello s. Expert Opin Biol Ther. 2024 Apr;24(4):217-219. doi: 10.1080/14712598.2024.2337242. Epub 2024 Apr 1. Expert Opin Biol Ther. 2024. PMID: 38557408 No abstract available.
Secondary laryngeal and pulmonary syphilis: A case report.
Borriello S, Delmonte S, Bisciari T, Mastorino L, Ribero S, Quaglino P. Borriello S, et al. J Eur Acad Dermatol Venereol. 2024 Feb 19. doi: 10.1111/jdv.19835. Online ahead of print. J Eur Acad Dermatol Venereol. 2024. PMID: 38372430 No abstract available.
A case of treatment-refractory psoriasis as the first manifestation of an HIV-infection.
Boskovic S, Merli M, Dapavo P, Siliquini N, Borriello S, Sciamarrelli N, Aquino C, Mastorino L, Burzi L, Drappero E, Ferrara M, Ribero S, Quaglino P. Boskovic S, et al. Among authors: borriello s. Ital J Dermatol Venerol. 2024 Feb;159(1):68-69. doi: 10.23736/S2784-8671.23.07656-9. Epub 2023 Nov 28. Ital J Dermatol Venerol. 2024. PMID: 38015571 No abstract available.
Drug survival and efficacy of anti-interleukin 23 biologics in psoriasis: a comparative study on different agents.
Roccuzzo G, Mastorino L, Susca S, Cariti C, Passerini SG, Sciamarrelli N, Borriello S, Macagno N, Sliquini N, Avallone G, Verrone A, Stroppiana E, Quaglino P, Ortoncelli M, Dapavo P, Ribero S. Roccuzzo G, et al. Among authors: borriello s. Clin Exp Dermatol. 2023 Mar 22;48(4):379-381. doi: 10.1093/ced/llac098. Clin Exp Dermatol. 2023. PMID: 36745578 No abstract available.
Tildrakizumab in real-life shows good efficacy in moderate-to-severe psoriasis regardless of previous use of biologic drugs and joint involvement.
Mastorino L, Cariti C, Susca S, Sciamarrelli N, Borriello S, Ortoncelli M, Stroppiana E, Verrone A, Dapavo P, Quaglino P, Ribero S. Mastorino L, et al. Among authors: borriello s. Dermatol Ther. 2022 Nov;35(11):e15818. doi: 10.1111/dth.15818. Epub 2022 Sep 22. Dermatol Ther. 2022. PMID: 36097346 No abstract available.